cofrogliptin + sodium-glucose cotransporter-2 inhibitor + metformin

This is a combination drug consisting of three components: - **Cofrogliptin** (a dipeptidyl peptidase-4 [DPP-4] inhibitor), which increases incretin levels, thereby increasing insulin secretion and decreasing glucagon secretion to lower blood glucose. - **Sodium-glucose cotransporter-2 (SGLT2) inhibitor**, a class of oral antidiabetic drugs that block SGLT2 in the kidneys, reducing glucose reabsorption and promoting urinary glucose excretion. This lowers blood sugar independently of insulin and provides additional benefits such as weight loss, reduced blood pressure, and cardiovascular/renal protection[1][3][5]. - **Metformin**, a biguanide that decreases hepatic glucose production, reduces intestinal absorption of glucose, and improves insulin sensitivity. The combination is intended for the treatment of type 2 diabetes mellitus to improve glycemic control through complementary mechanisms. SGLT2 inhibitors commonly used in such combinations include canagliflozin, dapagliflozin, empagliflozin, ertugliflozin among others[1][3][6]. The specific SGLT2 inhibitor in this formulation is not specified.